Holen Sie sich die Stockscreener-App
0.5826
6.83%
-0.0427
Vorhandelsmarkt:
.62
0.0374
+6.42%
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - PR Newswire
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8%Here's What Happened - MarketBeat
Citius Oncology (CTOR) expands Lymphir distribution to Europe through exclusive agreement with Uniphar - MSN
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius Oncology, Inc.: Fundamental Analysis and Financial Ratings | CTOR | US17331Y1091 - marketscreener.com
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Activity Recap: Will Citius Oncology Inc outperform small cap indexes2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com Australia
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data - TipRanks
Citius reports positive Phase 1 topline: 24% ORR, 48% CBR for LYMPHIR + pembrolizumab in gynecologic cancers - TradingView
Citius Oncology Announces Positive Topline Results from Investig - GuruFocus
Citius Oncology, Inc. Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of Lymphir in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - marketscreener.com
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - PR Newswire
Aug EndMonth: Can Citius Oncology Inc lead its sector in growthPortfolio Risk Summary & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Aug Highlights: Does Citius Oncology Inc have strong fundamentalsMarket Risk Analysis & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Finviz
Citius Oncology reports 86% response rate in lymphoma study By Investing.com - Investing.com Canada
Citius Oncology reports 86% response rate in lymphoma study - Investing.com
Citius Oncology, Inc. announces preliminary topline data from its study in high-risk diffuse large B-cell lymphoma patients - Bitget
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Citius Oncology reports 86% ORR and favorable safety for LYMPHIR prior to commercial CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma – Company Announcement - Financial Times
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz
New Jersey tax program turns Citius Pharma losses into $3.8M cash - Stock Titan
CTOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Outlook: Can Citius Oncology Inc keep up with sector leadersJuly 2025 Highlights & High Accuracy Buy Signal Tips - baoquankhu1.vn
Aug Selloffs: What are Merus NVs earnings expectationsMarket Weekly Review & Smart Swing Trading Alerts - baoquankhu1.vn
Aug Drivers: Is TCRT stock showing strong momentumMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Is Citius Oncology Inc. stock a contrarian buyTrade Exit Summary & Growth Oriented Trading Recommendations - mfd.ru
Analysts Are Bullish on Top Healthcare Stocks: Citius Oncology (CTOR), Autolus Therapeutics (AUTL) - The Globe and Mail
Aug PreEarnings: Can Citius Oncology Inc lead its sector in growth2025 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Armistice Capital reports 8.08M Citius Oncology (NASDAQ: CTOR) stake - Stock Titan
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - marketscreener.com
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ (PR Newswire) - Aktiellt
Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal - Indian Pharma Post
CTOR PE Ratio & Valuation, Is CTOR Overvalued - Intellectia AI
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR - The Malaysian Reserve
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates - MarketBeat
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):